logo

For the Inventor, By the Inventor

Tübingen, Germany

Hans-Georg Rammensee

This inventor holds 68 USPTO granted patents and 20 published patent applications and 3 EPO patents, primarily in Cancer Immunotherapy (CPC class C07K). Top assignee: Immatics Biotechnologies Gmbh. Active years: 2006-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans-Georg Rammensee. Retrieved from https://idiyas.com/inventor/hans-georg-rammensee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 68 

% Patents Active = 67.6


Average Co-Inventor Count = 4.7

ph-index = 11

Forward Citations = 445(Granted Patents)

Forward Citations (Not Self Cited) = 312(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Tubingen-Unterjessingen, DE (2006)
  • Tübingen-Unterjesigen, DE (2010)
  • Tübingen-Unterjesingen, DE (2011)
  • Tuebingen-Unterjesingen, DE (2012)
  • Unterjesingen, DE (2018 - 2022)
  • Tuebingen, DE (2014 - 2024)

Company Filing History:

goldMedal67 out of 728 
 
Immatics Biotechnologies Gmbh
 patents
where one patent can have more than one assignee

Years Active: 2006-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Peptides
Immunotherapy
Ovarian Cancer
Leukemias
Myeloma
Cell Epitopes
Tumor Targeting
Cancer Treatment
Combination Therapies
Cancer Vaccines
Epithelial Cancer
Acute Myeloid Leukemia
68 patents (USPTO):Explore Patents
1. 12098183 - Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers (2024-09-24),
2. 12065477 - Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers (2024-08-20),
3. 11919940 - Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers (2024-03-05),
4. 11858978 - Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers (2024-01-02),
5. 11840562 - Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers (2023-12-12),
6. 11819518 - Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers (2023-11-21),
7. 11806366 - Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers (2023-11-07),
8. 11560405 - Peptides and combination thereof for use in the immunotherapy against cancers (2023-01-24),
9. 11559550 - Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers (2023-01-24),
10. 11542303 - Peptides and combination thereof for use in the immunotherapy against cancers (2023-01-03),
11. 11427614 - Peptides and combination thereof for use in the immunotherapy against cancers (2022-08-30),
12. 11345737 - Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers (2022-05-31),
13. 11278571 - Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers (2022-03-22),
14. 11248035 - Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers (2022-02-15),
15. 11246889 - Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers (2022-02-15),

Title: The Innovative Mind of Hans-Georg Rammensee

Introduction: Hans-Georg Rammensee is a distinguished inventor hailing from Tuebingen, Germany. His groundbreaking work in the field of biotechnology has revolutionized the way we approach healthcare and disease prevention.

Latest Patents: Hans-Georg Rammensee holds several patents in the field of immunology and personalized medicine, focusing on novel approaches to cancer treatment and vaccine development.

Career Highlights: With a career spanning over three decades, Rammensee has made significant contributions to the scientific community. He is renowned for his research on antigen presentation and T-cell recognition, which has paved the way for innovative therapies.

Collaborations: Throughout his career, Hans-Georg Rammensee has collaborated with leading researchers and institutions worldwide, fostering a culture of innovation and knowledge exchange in the scientific community.

Conclusion: Hans-Georg Rammensee's dedication to pushing the boundaries of scientific discovery and his passion for improving global health outcomes make him a true pioneer in the field of biotechnology. His innovative spirit continues to inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…